Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adrenal Cortical Cancer Clear all
Completed No phase listed Observational

Adrenal Vein Sampling International Study (AVIS Study)

NCT01234220
View directory record Official record
Conditions
Hyperaldosteronism
Interventions
Not listed
Lead sponsor
University Hospital Padova
Other
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Dallas, Texas • Menomonee Falls, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 4, 2026, 8:52 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

NCT01898715
View directory record Official record
Conditions
Adrenocortical Carcinoma, Adrenal Cancer, ACC
Interventions
ATR-101
Drug
Lead sponsor
Millendo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Tampa, Florida • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 4, 2026, 8:52 AM EDT
Not yet recruiting Phase 1 Interventional

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

NCT07715903
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
Interventions
Carfilzomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 8:52 AM EDT
Terminated No phase listed Observational

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)

NCT04447014
View directory record Official record
Conditions
Adrenocortical Carcinoma, Adrenocortical Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 4, 2026, 8:52 AM EDT
Active, not recruiting No phase listed Observational

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)

NCT04358107
View directory record Official record
Conditions
Adrenocortical Carcinoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 4, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
CORT125134
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 4, 2026, 8:52 AM EDT
Recruiting Phase 2 Interventional

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

NCT06006013
View directory record Official record
Conditions
Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma, Stage III Adrenal Cortex Carcinoma, Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma
Interventions
Pembrolizumab, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging
Biological · Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 4, 2026, 8:52 AM EDT
Terminated Phase 2 Interventional Results available

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

NCT00778817
View directory record Official record
Conditions
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
Interventions
IMC-A12, mitotane
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Decatur, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 4, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 4, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

NCT02150213
View directory record Official record
Conditions
Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Interventions
MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram, Biopsy, BGG492
Procedure · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Tallahassee, Florida • Baltimore, Maryland • Hoffman, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 4, 2026, 8:52 AM EDT
Completed No phase listed Observational

Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging

NCT00445718
View directory record Official record
Conditions
Adrenocortical Carcinoma, Localized Resectable Neuroblastoma, Precancerous Condition
Interventions
computed tomography, 3-Tesla magnetic resonance imaging, Abdominal Sonogram
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 6 Months
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
38
States / cities
Tucson, Arizona • Downey, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 4, 2026, 8:52 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

NCT00264433
View directory record Official record
Conditions
Neoplasms
Interventions
ADH -1 (Exherin™)
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Fort Myers, Florida • Chapel Hill, North Carolina • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2007 · Synced Oct 4, 2026, 8:52 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer

NCT02720484
View directory record Official record
Conditions
Metastatic Carcinoma in the Adrenal Cortex, Recurrent Adrenal Cortex Carcinoma, Stage III Adrenal Cortex Carcinoma, Stage IV Adrenal Cortex Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab
Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 4, 2026, 8:52 AM EDT
Active, not recruiting Phase 2 Interventional

Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma

NCT03127774
View directory record Official record
Conditions
Adrenocortical Carcinoma, Peritoneal Carcinomatosis
Interventions
Cisplatin, Sodium thiosulfate, Cytoreductive surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 4, 2026, 8:52 AM EDT
Recruiting Phase 3 Interventional

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

NCT03583710
View directory record Official record
Conditions
ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma
Interventions
Cisplatin, Etoposide, Mitotane, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 4, 2026, 8:52 AM EDT
Completed Phase 1 Interventional

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

NCT00436657
View directory record Official record
Conditions
Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Adrenocortical Carcinoma, Wilms Tumor, Rhabdomyosarcoma, Desmoplastic Small Round Cell Tumor
Interventions
CHPP of Cisplatin, Abdominal Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 4, 2026, 8:52 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of 68Ga-R8760

NCT05999292
View directory record Official record
Conditions
Adrenocortical Carcinoma
Interventions
68Ga-R8760 injection at pre-defined dose levels, 68Ga-R8760 injection
Drug
Lead sponsor
Radionetics Oncology
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 4, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer

NCT01255137
View directory record Official record
Conditions
Adrenal Cortex Neoplasms
Interventions
Axitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 4, 2026, 8:52 AM EDT
Recruiting No phase listed Observational

International Pediatric Adrenocortical Tumor Registry

NCT00700414
View directory record Official record
Conditions
Adrenocortical Tumor
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2040
U.S. locations
5
States / cities
Stanford, California • St. Petersburg, Florida • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 4, 2026, 8:52 AM EDT
Recruiting Phase 1 Interventional

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

NCT06487481
View directory record Official record
Conditions
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC), Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
Interventions
Surgical resection, Preoperative RT
Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00569582
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 4, 2026, 8:52 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

NCT06900595
View directory record Official record
Conditions
Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8, Stage IV Adrenal Cortical Carcinoma AJCC v8, Unresectable Adrenal Cortical Carcinoma
Interventions
Biospecimen Collection, Cabozantinib, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
81
States / cities
Phoenix, Arizona • La Jolla, California • Madera, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 8:52 AM EDT
Not listed Not applicable Interventional

The Effects of Case Management in a Medicaid Managed Care Plan

NCT00385879
View directory record Official record
Conditions
Neoplasms, Heart Diseases, Adrenal Cortex Diseases
Interventions
Case management
Behavioral
Lead sponsor
Metropolitan Jewish Health System
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2006 · Synced Oct 4, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

NCT00071058
View directory record Official record
Conditions
Adrenal Cortex Neoplasms
Interventions
XR9576 (Tariquidar)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 4, 2026, 8:52 AM EDT